Biofrontera Inc (BFRI)vsZoetis Inc (ZTS)
BFRI
Biofrontera Inc
$0.93
+5.09%
HEALTHCARE · Cap: $11.97M
ZTS
Zoetis Inc
$77.80
-0.55%
HEALTHCARE · Cap: $32.80B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 20528% more annual revenue ($9.53B vs $46.17M). ZTS leads profitability with a 27.7% profit margin vs -13.8%. ZTS earns a higher WallStSmart Score of 58/100 (C).
BFRI
Hold37
out of 100
Grade: F
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BFRI.
Margin of Safety
+10.3%
Fair Value
$143.36
Current Price
$77.80
$65.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.9% year-over-year
Reasonable price relative to book value
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Trading at 10.2x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : BFRI
The strongest argument for BFRI centers on Revenue Growth, Price/Book. Revenue growth of 32.9% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : BFRI
The primary concerns for BFRI are EPS Growth, Market Cap, Debt/Equity.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
BFRI profiles as a hypergrowth stock while ZTS is a declining play — different risk/reward profiles.
BFRI carries more volatility with a beta of 0.88 — expect wider price swings.
BFRI is growing revenue faster at 32.9% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (58/100 vs 37/100), backed by strong 27.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biofrontera Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Biofrontera Inc., a biopharmaceutical company, develops and supplies dermatological products for the treatment of skin conditions in the United States. The company is headquartered in Woburn, Massachusetts.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?